Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
Mangoceuticals (NASDAQ:MGRX) versus Lipocine (NASDAQ:LPCN) Financial Contrast
John Higuchi Buys 40,000 Shares of Lipocine (NASDAQ:LPCN) Stock
Lipocine (NASDAQ:LPCN) CEO Mahesh Patel Acquires 25,000 Shares of Stock
What's Going On With Lipocine Stock On Monday?
Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
2026 Asset Growth: Why Federal Compliance Is the New Metric
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL)
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025
Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024
Lipocine Announces FDA Labeling Changes for Testosterone Products
Lipocine Receives Updated Regulatory Guidance on LPCN 1154
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024